uniQure (QURE) has shared an announcement.
uniQure N.V. has reached a significant milestone by administering the first dose in a Phase I/IIa clinical trial of AMT-191, their experimental treatment for Fabry disease. This progress may interest investors and those following biotech advancements, highlighting the company’s ongoing efforts to combat this genetic disorder.
Learn more about QURE stock on TipRanks’ Stock Analysis page.